SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Generic competition and market exclusivity periods in pharmaceuticals
7 references·15 citing·41 second hop
Generic competition and market exclusivity periods in pharmaceuticals (2007)Generic competition and market exclusivit…Generic Drug Industry Dynamics (2005)Generic Drug Industry DynamicsThe price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Returns on Research and Development for 1990s New Drug Introductions (2002)Returns on Research and Devel…Entry Decisions in the Generic Pharmaceutical Industry (1999)Entry Decisions in the Generi…Entry Decisions in the Generic Pharmaceutical Industry (1997)Entry Decisions in the Generi…Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug in…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Competition and R&D Financing: Evidence From the Biopharmaceutical Industry (2021)Competition and R&D Financing…Tertiary patenting on drug–device combination products in the United States (2018)Tertiary patenting on drug–de…How Reliable Is the Market for Technology? (2018)How Reliable Is the Market fo…Updated trends in US brand-name and generic drug competition (2016)Updated trends in US brand-na…Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Regulation and welfare: evide…Biosimilars: How Can Payers Get Long-Term Savings? (2016)Biosimilars: How Can Payers G…The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation (2015)The Roles Of Patents And Rese…The Case for Tailoring Patent Awards Based on the Time-to-Market of Inventions (2013)The Case for Tailoring Patent…Recent trends in brand-name and generic drug competition (2013)Recent trends in brand-name a…Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 (2013)Development of the generic dr…When Do Generics Challenge Drug Patents? (2011)When Do Generics Challenge Dr…Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry (2011)Regulation and Welfare: Evide…An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences (2011)An Empirical Review of Major …Balancing Innovation and Access: Patent Challenges Tip the Scales (2009)Balancing Innovation and Acce…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…Industrial Market Structure and Economic Performance. (1971)Product differentiation advantages of pioneering brands (1980)Generic Entry and the Pricing of Pharmaceuticals (1997)Uncertainty and Learning in Pharmaceutical Demand (2005)Killer Acquisitions (2020)Cost of innovation in the pharmaceutical industry (1991)An R&D Race with Knowledge Accumulation (2003)Cutting the cost of drug development? (2004)The Pharmaceutical Industry (2013)On the Misuse of Accounting Rates of Return to Infer Monopoly Profits (2016)Economic Welfare and the Allocation of Resources for Invention (1962)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Global Health and Foreign Policy (2010)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)Appropriating the Returns from Industrial Research and Development (1987)Drug Patents at the Supreme Court (2013)What is the impact of intellectual property rules on access to medicines? A systematic review (2022)Is Technological Change In Medicine Worth It? (2001)The Value of Improving the Productivity of the Drug Development Process (2002)Firm growth and R&D expenditure (2009)US biopharmaceutical finance and the sustainability of the biotech business model (2011)Automobile Prices in Market Equilibrium (1995)The Regulation of Entry (2000)Discrete Choice Methods with Simulation (2003)THE WELFARE IMPACT OF PARALLEL IMPORTS: A STRUCTURAL APPROACH APPLIED TO THE GERMAN MARKET FOR ORAL ANTI‐DIABETICS (2014)Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry (2017)Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry (1991)Estimation of a Model of Entry in the Airline Industry (1992)Strategic Brand Management: Building, Measuring, and Managing Brand Equity (1997)A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION* (2010)Physician Agency and Adoption of Generic Pharmaceuticals (2012)High Generic Drug Prices and Market Competition (2017)Industry Structure, Market Rivalry, and Public Policy (1973)Specification Tests in Econometrics (1978)Generic entry, price competition, and market segmentation in the prescription drug market (2007)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration (2010)Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration (2011)Patents and the Global Diffusion of New Drugs (2015)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 2005Generic Drug Industry Dynamics312 cited
  • 2002Returns on Research and Development for 1990s New Drug Introductions311 cited
  • 1999Entry Decisions in the Generic Pharmaceutical Industry228 cited
  • 1994Returns to R&D on new drug introductions in the 1980s197 cited
  • 1997Entry Decisions in the Generic Pharmaceutical Industry170 cited

Cited by

  • 2016Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry124 cited
  • 2011When Do Generics Challenge Drug Patents?100 cited
  • 2009Balancing Innovation and Access: Patent Challenges Tip the Scales96 cited
  • 2011Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry96 cited
  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2016Biosimilars: How Can Payers Get Long-Term Savings?86 cited
  • 2015The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation77 cited
  • 2013

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984
74 cited
  • 2013Recent trends in brand-name and generic drug competition69 cited
  • 2016Updated trends in US brand-name and generic drug competition68 cited
  • 2011An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences62 cited
  • 2021Competition and R&D Financing: Evidence From the Biopharmaceutical Industry46 cited
  • 2018Tertiary patenting on drug–device combination products in the United States24 cited
  • 2018How Reliable Is the Market for Technology?12 cited
  • 2013The Case for Tailoring Patent Awards Based on the Time-to-Market of Inventions7 cited